FibroGen to Report Second Quarter 2023 Financial Results
24 Julho 2023 - 8:00AM
FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2023
financial results on Monday, August 7 after the market close.
FibroGen will also conduct a conference call on that day at 5:00 PM
Eastern Time with the investment community to further detail the
company's corporate and financial performance.
Conference Call and Audio Webcast Interested
parties may access a live audio webcast of the conference call via
the “Investor Relations” page of the Company’s website at
www.fibrogen.com. To access the call by phone, please go to this
link (registration link), and you will be provided with dial-in
details. To avoid delays, we encourage participants to dial in to
the conference call fifteen minutes ahead of the scheduled start
time. A replay of the webcast will also be available for a limited
time at the following link (webcast replay).
About FibroGen FibroGen, Inc. is a
biopharmaceutical company committed to discovering, developing, and
commercializing a pipeline of first-in-class therapeutics. The
Company applies its pioneering expertise in connective tissue
growth factor (CTGF) biology and hypoxia-inducible factor (HIF) to
advance innovative medicines for the treatment of unmet needs.
Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical
development for the treatment of locally advanced unresectable
pancreatic cancer (LAPC), metastatic pancreatic cancer, and
ambulatory Duchenne muscular dystrophy (DMD). Roxadustat (爱瑞卓®,
EVRENZOTM) is currently approved in China, Europe, Japan, and
numerous other countries for the treatment of anemia in CKD
patients on dialysis and not on dialysis. Roxadustat is in clinical
development for chemotherapy-induced anemia (CIA) in China.
FibroGen recently expanded its research and development portfolio
to include product candidates in the immuno-oncology space along
with an exclusive license for FOR46. For more information, please
visit www.fibrogen.com.
Forward-Looking Statements This release
contains forward-looking statements regarding FibroGen’s strategy,
future plans and prospects, and the development and
commercialization of the company’s product candidates. These
forward-looking statements include, but are not limited to,
statements about FibroGen’s plans and objectives and typically are
identified by use of terms such as “may,” “will”, “should,” “on
track,” “could,” “expect,” “plan,” “anticipate,” “believe,”
“estimate,” “predict,” “potential,” “continue” and similar words,
although some forward-looking statements are expressed differently.
FibroGen’s actual results may differ materially from those
indicated in these forward-looking statements due to risks and
uncertainties related to the continued progress and timing of its
various programs, including the enrollment and results from ongoing
and potential future clinical trials, and other matters that are
described in our Annual Report on Form 10-K for the fiscal year
ended December 31, 2022 and our Quarterly Report on Form 10-Q for
the quarter ended March 31, 2023, each as filed with the Securities
and Exchange Commission (SEC), including the risk factors set forth
therein. Investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
of this release, and FibroGen undertakes no obligation to update
any forward-looking statement in this press release, except as
required by law.
Contacts: FibroGen, Inc.
Investors:Meichiel KeenanInvestor Relations and
Corporate Communicationsmkeenan@fibrogen.com
Media:Michael Szumeramszumera@fibrogen.com
FibroGen (NASDAQ:FGEN)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
FibroGen (NASDAQ:FGEN)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024